Generic Medicine Info
Indications and Dosage
Adult: 2.5 mg twice wkly; the 1st dose is taken on the 1st day of the menstrual cycle with the 2nd dose taken 3 days later; thereafter the doses should be taken on the same 2 days of each wk, usually for a period of 6 mth. If a dose is missed: Take 2.5 mg as soon as possible and maintain original dose sequence; if 2 or more missed doses: Discontinue, restart on 1st day of new cycle after a -ve pregnancy test.
May be taken with or without food.
Metabolic and/or vascular disorders during previous oestrogen and/or progestogen therapy. Thromboembolic disorders; marked hepatic, cardiac or kidney dysfunction; undiagnosed genital bleeding, androgen-dependent tumors; pregnancy, lactation.
Special Precautions
Conditions which may be adversely affected by fluid retention. History of thrombosis; childn and adolescents; diabetes mellitus, polycythemia. Nonhormonal contraception is recommended. withdraw in the event of androgenic effects. Monitor liver function during treatment.
Adverse Reactions
Menstrual disturbances. Acne, oily skin, fluid retention, wt gain, hirsutism, voice change, headache, GI disturbances, altered libido, hot flushes, breast size reduction, nervousness, change in appetite, muscle cramp, depression, arthralgia, isolated cases of benign intracranial hypertension.
Drug Interactions
Antiepileptic drugs, rifampicin, oral contraceptives.
Lab Interference
Increased liver enzyme values.
Mechanism of Action: Gestrinone is a synthetic steroidal hormone which has androgenic, anti-estrogenic and antiprogestogenic properties.
MIMS Class
Oestrogens, Progesterones & Related Synthetic Drugs
Disclaimer: This information is independently developed by MIMS based on Gestrinone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in